News

News

 

June 2018

Prof. Pierre van der Bruggen joins APO-T's Scientific Advisory Board.

 

May 2018

Dr Allard Kaptein joins APO-T's Scientific Advisory Board.

 

January 2018

APO-T appoints dr Marta Kijanka as acting CEO in the period before a new chief executive starts.

 

APO-T starts a collaboration with the group of prof. Judith Klumperman (UMCU) to work on Advanced CLEM imaging of antibodies targeting low expressing, clinically relevant cancer targets for the development of ADCs. This work is performed within a grant obtained from ZonMw.

 

December 2017

Johan Renes (CEO) and dr Paul Steverink (CFO) have decided to leave the company .

 

August 2015

APO-T appoints Dr. Marta Kijanka as Vice-President of R&D.

 

February 2015

APO-T opens new laboratory and office facilities at PivotPark in Oss, the Netherlands, and expands its R&D staff.

 

 

April 2014

The Netherlands Enterprise Agency (RvO) grants APO-T an “Innovation Credit” for the development of its AIM therapy for the treatment of i.a. AML/MM. The credit consists of an investment of €1.5 million to support preclinical studies and a planned Phase I/II study.

 

March 2014

Dutch biotech company APO-T announces the successful completion of a Series B equity financing round by existing shareholders participating. The proceeds will be used to accelerate the clinical development of APO-T's proprietary AIM technology and to expand the company’s capabilities in the area of formats such as ADC's.

 

September 2013

APO-T expands its Executive Board with Dr. Erwin Houtzager as Chief Scientific Officer. Erwin Houtzager (1962; PhD Molecular Biology) is a seasoned professional in pre-clinical antibody development. He has been working from 1998 till 2001 at Ubisys at which he formed the basis for Crucell after a merger with Introgene. In 2001 Erwin founded Catchmabs.

 

 

September 2013

APO-T B.V. and LinXis B.V. both privately held oncology companies, announced that LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates (ADC) using APO-T’s MAGE-HLA targeted antibodies and LinXis’ unique LX linker technology. In exchange, LinXis will receive certain milestone payments upon the achievement of e.g. clinical development and sales milestones, and royalties on worldwide net sales resulting from commercialized products.